EU Regulator Backs Lilly's Oral GLP-1 and Revolution Medicines' Pancreatic Cancer Drug

· Health · European Union · United States

The European Medicines Agency's human medicines committee (CHMP) endorsed Eli Lilly's oral GLP-1 pill orforglipron, giving the company a regulatory boost as it works to close the gap with Novo Nordisk, whose rival Wegovy pill is already on the market. In the same round of recommendations, European regulators recommended approval of Revolution Medicines' drug Rasonque for pancreatic cancer, following an earlier green light from the US FDA. The CHMP opinions are a key step before formal European Commission authorization, and both products target large, competitive markets. For Lilly, an oral GLP-1 could widen access beyond injectable formats in the obesity and diabetes field, while the pancreatic cancer recommendation adds a new option in a tumor type with few effective treatments.

Why it matters：European backing for an oral GLP-1 sharpens competition in the fast-growing obesity and diabetes market, while the pancreatic cancer recommendation shows regulators moving new oncology drugs toward approval and could shape treatment options and investor expectations in both areas.

Key points

  • CHMP endorsed Lilly's orforglipron, an oral GLP-1 pill, as Lilly seeks to catch up with Novo's Wegovy pill.
  • European regulators also recommended approval of Revolution Medicines' Rasonque for pancreatic cancer, after the FDA had already cleared it.
  • Both recommendations would still need formal European Commission authorization before launch.

Sources (original reporting)

More stories from this day